Globus Medical Inc. (GMED) reported fourth-quarter 2025 results with revenue of $826.4 million, up 25.7% year‑over‑year, driven by stronger margins and higher sales volume.
Cash flow and balance-sheet highlights:
Against expectations, revenue exceeded the consensus of $815.1 million, while diluted EPS of $1.03 came in below the estimate of $1.17. Overall, Globus Medical (GMED) posted sizable year‑over‑year improvements in profitability and operating cash flow alongside higher capital investment.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Globus Medical Inc. Insider Trading Activity
Globus Medical Inc. insiders have traded $GMED stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:
- DAVID D DAVIDAR sold 25,000 shares for an estimated $2,150,005
- STEPHEN T ZARRILLI sold 25,000 shares for an estimated $2,107,257
- KYLE KLINE (Senior Vice President, CFO) has made 0 purchases and 2 sales selling 22,136 shares for an estimated $2,032,133.
- KELLY HULLER (EVP, GC, Corporate Secretary) has made 0 purchases and 2 sales selling 17,500 shares for an estimated $1,551,700.
- ANN D RHOADS has made 0 purchases and 3 sales selling 20,000 shares for an estimated $1,402,600.
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 6,000 shares for an estimated $557,600.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Globus Medical Inc. Hedge Fund Activity
We have seen 260 institutional investors add shares of Globus Medical Inc. stock to their portfolio, and 323 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVESCO LTD. added 3,595,339 shares (+1235.2%) to their portfolio in Q4 2025, for an estimated $313,909,048
- BANK OF MONTREAL /CAN/ added 3,351,380 shares (+15317.1%) to their portfolio in Q4 2025, for an estimated $292,608,987
- CITADEL ADVISORS LLC added 2,427,303 shares (+2165.4%) to their portfolio in Q4 2025, for an estimated $211,927,824
- HAWK RIDGE CAPITAL MANAGEMENT LP removed 1,569,235 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $137,009,907
- AXA S.A. removed 1,528,531 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $87,538,970
- VAN BERKOM & ASSOCIATES INC. removed 1,333,111 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $116,393,921
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 1,104,755 shares (+129818.4%) to their portfolio in Q4 2025, for an estimated $96,456,159
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Globus Medical Inc. Government Contracts
We have seen $1,040,324 of award payments to $GMED over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROS POST SURGERY: $43,116
- 4568294217!CREO STABILIZATION SYSTEM: $36,585
- 4568393139!CREO STABILIZATION SYSTEM: $34,366
- PRECICE 2 NAIL / VARIOUS: $32,065
- A GLOBUS PRECISE INTRAMEDULLARY NAIL SYSTEM IS REQUIRED FOR A PATIENT (FOR LIMB LENGTHENING SURGERY): $32,065
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Globus Medical Inc. Analyst Ratings
Wall Street analysts have issued reports on $GMED in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/17/2025
- Truist Securities issued a "Buy" rating on 11/18/2025
- Barclays issued a "Overweight" rating on 11/10/2025
- Wells Fargo issued a "Overweight" rating on 11/07/2025
- B of A Securities issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for Globus Medical Inc., check out Quiver Quantitative's $GMED forecast page.
Globus Medical Inc. Price Targets
Multiple analysts have issued price targets for $GMED recently. We have seen 11 analysts offer price targets for $GMED in the last 6 months, with a median target of $100.0.
Here are some recent targets:
- David Saxon from Needham set a target price of $112.0 on 01/30/2026
- Caitlin Cronin from Canaccord Genuity set a target price of $112.0 on 01/09/2026
- Matt O'Brien from Piper Sandler set a target price of $115.0 on 01/08/2026
- Shagun Singh from RBC Capital set a target price of $100.0 on 12/17/2025
- Keith Hinton from Freedom Capital Markets set a target price of $87.0 on 12/17/2025
- Drew Ranieri from Morgan Stanley set a target price of $100.0 on 12/02/2025
- Richard Newitter from Truist Securities set a target price of $105.0 on 11/18/2025
